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licenses/by/4.0/).Abstract Background: An association between BRCA pathogenic variants and an increased
endometrial cancer risk, specifically serous-like endometrial cancer, has been postulated but
remains unproven, particularly for BRCA2 carriers. Mechanistic evidence is lacking, and
any link may be related to tamoxifen exposure or testing bias. Hysterectomy during risk-
reducing bilateral salpingo-oophorectomy is, therefore, of uncertain benefit. Data from a
large, prospective cohort will be informative.
Methods: Data on UK BRCA pathogenic variant carriers were interrogated for endometrial
cancer diagnoses. Standardised incidence ratios (SIRs) were calculated in four distinct cohorts
using national endometrial cancer rates; either from 1/1/1980 or age 20, prospectively from
date of personal pathogenic variant report, date of family pathogenic variant report or date
of risk-reducing salpingo-oophorectomy. Somatic BRCA sequencing of 15 serous endometrial
cancers was performed to detect pathogenic variants.
Results: Fourteen cases of endometrial cancer were identified in 2609 women (1350 BRCA1
and 1259 BRCA2), of which two were prospectively diagnosed. No significant increase inentre for Genomic Medicine, St Mary’s Hospital, Oxford Road, Manchester, M13 9WL, UK.
hs.uk (D.G. Evans).
ed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
S.J. Kitson et al. / European Journal of Cancer 136 (2020) 169e175170either overall or serous-like endometrial cancer risk was identified in any of the cohorts exam-
ined (SIRZ 1.70, 95% confidence intervalZ 0.74e3.33; no cases of serous endometrial cancer
diagnosed). Results were unaffected by the BRCA gene affected, previous breast cancer or
tamoxifen use. No BRCA pathogenic variants were detected in any of the serous endometrial
cancers tested.
Conclusions: Women with a BRCA pathogenic variant do not appear to have a significant
increased risk of all-type or serous-like endometrial cancer compared with the general popu-
lation. These data provide some reassurance that hysterectomy is unlikely to be of significant
benefit if performed solely as a preventive measure.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Since the publication of a number of reports
describing diagnoses of serous endometrial cancer in
BRCA1 pathogenic variant carriers of Ashkenazi Jewish
heritage [1e3], there has been interest in a potential
association between the BRCA pathogenic variants and
an increased risk of endometrial cancer. A number of
studies have sought to quantify the level of risk,
although with conflicting results, with some finding ev-
idence of an increased risk [4e6], particularly in BRCA1
carriers, whilst others have found no association [7,8].
Unfortunately, the absence of a suitable control group
has prevented the results of these earlier studies being
reconciled in a meta-analysis [9]. From a biological
perspective, should a causative relationship exist be-
tween BRCA pathogenic variants and endometrial
cancer, it would be anticipated that the increased risk
would be restricted to the serous-like histological sub-
type, including p53 mutant uterine carcinosaromas and
mixed epithelial carcinomas [10]. This has, however, not
always been observed [11,12]. It has also been postulated
that any observed association may be due to the use of
tamoxifen for the prevention and treatment of breast
cancer rather than a consequence of a BRCA1 or
BRCA2 pathogenic variant per se [13,14]. Whilst several
prospective studies have examined the incidence of
endometrial cancer after risk-reducing salpingo-
oophorectomy (RRSO) in BRCA1 and BRCA2 patho-
genic variant carriers compared with the general popu-
lation, they have failed to consider the impact of the
procedure on the rate of endometrial cancer within this
specific population [12,13]. Debate, therefore, continues
within the scientific and medical communities as to
whether risk-reducing hysterectomy should be offered to
women with BRCA1 and BRCA2 pathogenic variants at
the time of their RRSO to reduce their subsequent
endometrial cancer risk[11,15]. Limitations of the
studies performed to date are that they have often been
purely retrospective, have included only small numbers
of BRCA pathogenic variant carriers, particularly those
with BRCA2 pathogenic variants, and have frequentlyomitted to undertake expert pathological review of the
tumour tissue to ensure accurate subtyping. They have
also often had short follow-up durations of only 5e6
years, which, when applied to a cohort with a median
age of 40e50 years, means that they have limited power
to detect endometrial cancer cases which predominately
occur in older women. This study, therefore, sought to
determine whether BRCA pathogenic variants are
associated with an increased risk of endometrial cancer
compared with the general population using a large,
well-described cohort of BRCA1 and BRCA2 patho-
genic variant carriers with prospective follow-ups. It
also aimed to determine whether there was a particular
association between BRCA pathogenic variants and the
serous histological subtype of endometrial cancer and
the impact of RRSO on this risk.2. Materials and methods
A prospectively maintained database of BRCA patho-
genic variant carriers at the Manchester Centre for
Genomic Medicine was used to identify individuals aged
>20 years for analysis. Data were collected on date of
birth, personal and family pathogenic variant testing,
salpingo-oophorectomy  hysterectomy, breast, ovarian
and endometrial cancer diagnosis, death and date of the
last follow-up. Information on tamoxifen use was
collected wherever possible. Women were eligible for the
study if they had a BRCA1 or BRCA2 pathogenic
variant identified between 01/01/1991 (the start date of
the database) and 31/12/2017 and had not undergone a
previous hysterectomy. Pathology reports were collated
from affected individuals to determine endometrial
cancer subtype, with slide review by an expert gynae-
cological pathologist (J.B.) where possible and TP53
immunohistochemistry in accordance with previously
published protocols [16]. Follow-up data were collected
through medical record review and from the National
Cancer Registration and Analysis Service, for women
enrolled in the Epidemiological study of Familial Breast
Cancer (EMBRACE) study, a national cohort study of
BRCA1 and 2 pathogenic variant carriers and non-
S.J. Kitson et al. / European Journal of Cancer 136 (2020) 169e175 171affected family members [17]. Women were considered
in a number of distinct, but overlapping, cohorts;
retrospectively assuming the follow-up started on 1/1/
1980 (or age 20 years, whichever occurred later) and
prospectively from the date of their family BRCA
pathogenic variant identification (or age 20 years), from
date of their personal BRCA pathogenic variant identi-
fication (or age 20 years) and from date of RRSO, where
applicable. A nested case-control analysis was planned
to evaluate the competing effect of RRSO on endome-
trial cancer incidence; however, no cases of endometrial
cancer occurred in women who underwent RRSO.
Women were censored at time of hysterectomy, diag-
nosis of cancer of the ovary, fallopian tube or perito-
neum, death, the last follow-up or 31/12/17, whichever
occurred first.
To establish whether serous endometrial cancers are
associated with pathogenic variants in BRCA, we
identified 15 serous endometrial cancers treated at our
institution and carried out somatic BRCA sequencing.
DNA was extracted from formalin-fixed paraffin
embedded blocks of tumour tissue, which had been
obtained at the time of hysterectomy. DNA extraction
was performed using either COBAS (Cat no:
05985536190, Roche) or EZ1 (Cat no: 953034, Qiagen)
extraction kits. The DNA was quantified using Qubit
broad range assay and reagents. Sanger DNA
sequencing for BRCA1/2 mutations was undertaken by
the Manchester Genomics Diagnostics Laboratory
using their in-house developed protocol; details of which
have been published elsewhere [18]. In brief, 80 ng of
intact DNA was amplified using GeneRead DNAseq
Targeted Exon Enrichment Breast Panel (Qiagen). PCR
products were purified using Ampure XP beads and
quantified on the 2200 TapeStation using D1000 High
Sensitivity kit (Agilent). These were then adenylated,
and adaptors were ligated using TruSeq PCR-free Li-
brary Preparation Kit according to manufacturer’s
protocol (Illumina). The resulting libraries were cleaned
and selected for size using GeneRead (Qiagen) size se-
lection columns, before undergoing quantification using
the KAPA Library Quantification Kit (Kapa Bio-
systems). Each library was normalised to 0.5 nM with
EB buffer (Qiagen). Samples were pooled, denatured
with 0.2 N NaOH of equal volume, neutralised with
200 mM Tris of equal volume and diluted with HT1
solution (Illumina) to achieve a final 12.5pM library
concentration. For sequencing, 594uL of the pooled li-
brary mix and 6 pL of 12.5pM PhiX control library were
mixed and loaded on to MiSeq V.2 (Illumina). Data
were processed as previously described.
Expected endometrial cancer incidence rates were
calculated using age-standardised UK-specific data
available from the Office for National Statistics [19] in 5
year intervals and were adjusted for local hysterectomy
rates, as calculated using data from the Predicting the
Risk of Cancer At Screening (PROCAS) study [20]. Thiswas a large risk assessment study conducted in the
Greater Manchester area developing breast cancer risk
algorithms. The risk of endometrial cancer relative to
the general population was evaluated with standardised
incidence ratios (SIR), calculated as the observed num-
ber of endometrial cancer cases divided by the expected
number of cases. Subgroup analyses were performed
based on BRCA1/2 pathogenic variant status, history of
breast cancer and tamoxifen use and endometrial cancer
histological subtype. Serous-like endometrial cancers
included serous endometrial cancer, uterine carcinosar-
comas with a serous epithelial component and mixed
serous epithelial tumours in keeping with the findings of
de Jonge et al [10]. The expected number of serous-like
endometrial cancer cases was calculated assuming 10%
of all endometrial cancers were of the serous-like his-
totype [21,22] The Byar’s approximation of the exact
Poisson distribution was used to calculate the 95%
confidence limits using the methodology of Breslow and
Day [23]. Statistical analysis was performed using MS
Excel (2016).3. Results
Of 2609 women, 1350 (51.7%) had a BRCA1 pathogenic
variant and 1259 (48.3%) had a BRCA2 pathogenic
variant. The median age at baseline, the last follow-up
and the length of the follow-up varied according to the
cohort examined (Table 1).
There were 14 cases of endometrial cancer identified;
12 occurred before the confirmation of a personal
BRCA pathogenic variant (i.e. were identified retro-
spectively) and two cases were identified prospectively.
The clinical characteristics of the endometrial cancer
cases are given in Supplementary Table 1. Pathology
review was possible for six of the 14 endometrial cancer
cases identified, with TP53 immunohistochemistry per-
formed in three cases to aid diagnosis. Most cases were
of endometrioid subtype, with one retrospectively
identified case of a mixed serous and endometrioid
tumour and two cases of endometrial carcinosarcoma.
Only the mixed serous tumour demonstrated diffuse p53
staining, in keeping with a mutant-like pattern. Both
prospectively diagnosed endometrial cancer cases were
of endometrioid subtype and occurred in index cases.
There were two cases of proven synchronous ovarian
and endometrial cancers, one identified prospectively
and the other retrospectively, and a further suspected
case within the retrospective cohort, which could not be
confirmed as the original slides were not available for
review. There were no cases of endometrial cancer in
women who underwent RRSO.
The overall risk of endometrial cancer was not
significantly increased in any of the four cohorts studied
(from 1/1/1980 adjusted SIR Z 1.70, 95% confidence
interval [CI] Z 0.74e3.33; date of family pathogenic
Table 1
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0.12e3.02; date of personal pathogenic variant report
adjusted SIR Z 1.21, 95% CI Z 0.09e4.48; date of
RRSO adjusted SIR incalculable, Table 2).
Subgroup analyses failed to find any difference in
endometrial cancer risk between women with a BRCA1
or BRCA2 pathogenic variant, a history of breast cancer
or tamoxifen use. Neither was there a specific increase in
the risk of serous-like endometrial cancer (cohort from
1/1/1980 SIR Z 3.66, 95% CI Z 0.01e23.41, SIR
incalculable in the prospective cohorts as no cases of
serous endometrial cancer diagnosed).
Furthermore, we assessed the presence of a patho-
genic variant in BRCA1/2 in first-degree relatives, of a
proven carrier, who had developed endometrial cancer
without previous breast or synchronous ovarian cancer.
Five of seven (71%) did not carry the family variant. If
endometrial cancer was associated, then more than 50%
should have carried the pathogenic variant.
Of the 15 serous endometrial cancers analysed, none
contained BRCA1/2 pathogenic variants.4. Discussion
This study did not find a significant increase in the
incidence of endometrial cancer in women with a path-
ogenic variant in either the BRCA1 or BRCA2 genes.
This finding was unaffected by the BRCA gene affected,
a personal history of breast cancer or tamoxifen use.
The study was unable to address whether RRSO reduces
the risk of endometrial cancer specifically in this popu-
lation, due to the lack of endometrial cancer cases in
women who underwent RRSO. No specific association
between BRCA1/2 pathogenic variants and serous
endometrial cancer was detected; there was neither anincreased risk of serous endometrial cancer in BRCA1/2
pathogenic variant carriers nor were pathogenic variants
detected in the BRCA1/2 genes within the tumour tissue
from 15 unselected serous endometrial cancers.
These reassuring findings are consistent with those of
Levine et al. [7], who described a relative risk of endo-
metrial cancer of 0.75 (95% CI Z 0.24e2.34, pZ 0.6) in
199 Ashkenazi Jews with BRCA1/2, and of Lee et al.
[11], who failed to find an increase in serous or endo-
metrioid endometrial cancer in their moderately sized
Australasian population (BRCA1 SIR Z 2.87, 95% CI
Z 0.59e8.43, p Z 0.18, BRCA2 SIR Z 2.01, 95% CI Z
0.24e7.30, p Z 0.52). The largest study to date, con-
ducted across 11 different countries, however, yielded
contradictory results, noting a significantly increased
risk of endometrial cancer in BRCA1 pathogenic variant
carriers and those exposed to tamoxifen [5]. Of the 4893
women studied, 3536 were BRCA1 pathogenic variant
carriers, explaining why there was no statistically sig-
nificant increase in endometrial cancer risk in the
BRCA2 group, despite similar SIRs (BRCA1 SIR Z
1.91, 95% CI Z 1.06e3.19, p Z 0.03, BRCA2 SIR Z
1.75, 95% CI Z 0.55e4.23, p Z 0.2). The association
between tamoxifen use and an increase in endometrial
cancer incidence in BRCA pathogenic variant carriers
has been confirmed in a subsequent case-control study
undertaken by the same group, which found a 6.21-fold
increase in risk compared with non-users (95% CI Z
2.21e17.5, p Z 0.0005), which the authors suggested
could provide an explanation for the observed associa-
tion [14]. These findings were not, however, replicated in
the present study. Whilst the same authors also
described a lower incidence of endometrial cancer in
women who underwent oophorectomy for any reason,
this has not been confirmed in other cohorts of women
who have undergone specific RRSO, that is, in the
Table 2
Observed and expected endometrial cancer rates in BRCA pathogenic
variant carriers.





1980e1984 0.28 0 0.00 0.00 0
1985e1989 0.4 0 0.00 0.00 0
1990e1994 0.61 1 1.64 0.00 13.11
1995e1999 0.82 4 4.90 0.01 31.45
2000e2004 1.08 3 2.77 0.05 14.56
2005e2009 1.35 4 2.97 0.13 13.6
2010e2014 1.3 1 0.77 0.03 3.59
2015e2017 0.44 1 2.27 0.00 23.4
Total 6.27 14 2.23 0.84 4.78




0.82 3 3.66 0.01 23.41
BRCA1 only 3.68 7 1.9 0.47 5.05
Date of family pathogenic variant mutation report
1990e1994 0 0 0 0 0
1995e1999 0.05 1 19.39 0 1420.26
2000e2004 0.2 1 5.01 0 102.28
2005e2009 0.49 0 0 0 0
2010e2014 0.65 0 0 0 0
2015e2017 0.33 0 0 0 0
Total 1.71 2 1.17 0.1 4.6




0.23 0 0 0 0
BRCA1 only 0.98 1 1.02 0.01 5.73
Date of personal pathogenic variant mutation report
1990e1994 0 0 0 0 0
1995e1999 0.03 1 32.35 0 3906.24
2000e2004 0.14 1 7.33 0 212.49
2005e2009 0.37 0 0 0 0
2010e2014 0.5 0 0 0 0
2015e2017 0.22 0 0 0 0
Total 1.26 2 1.59 0.06 7.55




0.17 0 0 0 0
BRCA1 only 0.73 1 1.36 0 9.46
Date of RRSO
1990e1994 0.02 0 0 0 0
1995e1999 0.04 0 0 0 0
2000e2004 0.09 0 0 0 0
2005e2009 0.19 0 0 0 0
2010e2014 0.29 0 0 0 0
2015e2017 0.13 0 0 0 0
Total 0.76 0 0 0 0




0.10 0 0 0 0
BRCA1 only 0.47 0 0 0 0
CI, confidence interval; RRSO, risk-reducing salpingo-oophorectomy;
SIR, standardised incidence ratio.
a Expected data adjusted for hysterectomy prevalence data.
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effect of RRSO may have been anticipated if serous
endometrial cancers originate in the fallopian tube. The
fact that in our cohort only one case of mixed serous
and endometrioid endometrial cancer was diagnosed
means that we are unable to provide any robust data to
confirm or refute this hypothesis, except to state that
this case occurred in a woman who had not undergone
RRSO and no cases of endometrial cancer were diag-
nosed in the RRSO cohort.
The number of endometrial cancer cases observed in
each of the cohort studies, including our own, has been
small (2e17) and could well explain the difference in
statistical significance of SIRs that all approximate to a
value of 2. Indeed, only two cases of endometrial cancer
were diagnosed in our prospective cohorts, which may
indicate a testing bias in those with endometrial cancer
in previously reported studies. An unbiased assessment
of testing first-degree relatives with only endometrial
cancer supports our premise that there is unlikely to be
any substantial increase in endometrial cancer risk. It is,
however, arguable that even if an SIR of 2 is validated
(none of our upper confidence limits exclude this), the
level of risk is insufficient to recommend hysterectomy
at the time of bilateral salpingo-oophorectomy as a risk-
reducing measure. Given the increased potential
morbidity associated with more extensive surgery, evi-
dence of benefit is certainly warranted to outweigh these
additional risks. Whether there is a clear benefit in
specific subgroups of BRCA pathogenic variant carriers
is currently unknown; neither ours nor previously pub-
lished studies have included data on body mass index
(BMI) and hence have been unable to adjust for this in
analyses.
The strengths of this study include the confirmation
of endometrial cancer diagnoses with histological re-
ports and contemporaneous expert pathological review
of slides, although unfortunately this was not univer-
sally achievable due to the lack of availability of tumour
tissue for assessment. The study also included the largest
number of BRCA2 pathogenic variant carriers to date,
increasing our understanding of endometrial cancer risk
in this specific population. As with previous studies,
robust methodology has been employed to compare
observed with national expected endometrial cancer
rates, with adjustment made for local hysterectomy
rates. We were able to include data on BRCA1/2 path-
ogenic variant status of first-degree relatives of women
who developed endometrial cancer and of unselected
serous endometrial cancer cases to corroborate our
findings. Our somatic BRCA testing has been shown to
have high sensitivity in high-grade serous ovarian cancer
[25].
The potential lack of power in our study is a limita-
tion and one that we have attempted to address by
contacting the EMBRACE study (Easton D) to ensure
endometrial cancer cases have not been missed. It does
S.J. Kitson et al. / European Journal of Cancer 136 (2020) 169e175174mean that our ability to detect differences in endome-
trial cancer risk in any specific subgroups or subtype of
endometrial cancer is limited. Whilst the length of the
follow-up, particularly for the retrospective cohort, is a
clear advantage of this work, the median age at
censoring remains younger than 50 years, well below the
average age of endometrial cancer diagnoses in the UK
[24]. Re-analysis of the data at a later date will be per-
formed to increase the duration of the follow-up and
potentially the number of endometrial cancer diagnoses.
Subgroup analyses based upon tamoxifen use was
limited due to the fact that two thirds of women in the
database did not have data collected on their exposure
to the drug, although the vast majority of women with a
pathogenic variant in a BRCA gene without a history of
breast cancer were not known to have taken tamoxifen.
The low prevalence of tamoxifen use within the cohort
may well explain why no association was observed be-
tween tamoxifen use and an increase in endometrial
cancer risk. Additional efforts to reduce the amount of
missing data within our data set will be made to address
this. Data were unfortunately not routinely collected on
hormone replacement therapy (HRT) use by women
who underwent RRSO and so the impact of this on
subsequent endometrial cancer risk could not be
assessed. Whilst oestrogen-only HRT may be associated
with a lower rate of subsequent breast cancer [25,26],
this must be balanced against the impact this could have
on the risk of malignant changes within the endome-
trium. Whilst every attempt was made to undertake
histological review of all endometrial cancer cases
occurring within the cohort, this was unfortunately not
possible for eight cases where slides were unavailable.
Four of these cases were also operated on at another
hospital and, as it was not possible to retrieve the pa-
thology reports for these tumours, this may impact upon
the results of our subgroup analysis of serous-like
endometrial cancers.5. Conclusion
In conclusion, BRCA1 and BRCA2 pathogenic variant
carriers do not appear to be at a significant increased
risk of endometrial cancer compared with the general
population. Neither does there appear to be a specific
association between BRCA1/2 pathogenic variants and
serous endometrial cancer. Women and clinicians
should be reassured that hysterectomy at the time of
bilateral salpingo-oophorectomy is unlikely to be of
benefit if performed solely for the purpose of trying to
reduce subsequent endometrial cancer risk.Ethics approval and consent for publication
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Ethics Committee reference 15/NW/0733, Cancer
Research UK clinical trial database, ref-13595). The
study was performed in accordance with the Declaration
of Helsinki.
Data availability
The data that support the findings of this study are
available from the corresponding author upon request.
Funding
S.J.K. reports being a National Institute for Health
Research (NIHR) Academic Clinical Lecturer. N.A.J.R.
reports being a Medical Research Council Doctoral
Research Fellow (MR/M018431/1). E.J.C., E.R.W.,
C.B. and D.G.E. are supported through the NIHR
Manchester Biomedical Research Centre (IS-BRC1215-
20007), and D.G.E. reports being an NIHR Senior
Investigator (NFeSI-0513-10076).
Role of the funding source
The funding source had no role in the design of this
study, its execution, analysis, interpretation of the re-
sults or decision to submit the results.
Author contributions
E.J.C. and D.G.E. contributed in designing the study
and supervising its execution. F.L., E.R.W., R.D.C.,
R.J.E. and D.G.E. contributed in data collection. S.J.K.
performed the analyses and drafted the manuscript. C.B.
and N.A.J.R. contributed to data collection and anal-
ysis. J.B. provided pathological review of tumour slides.
All authors contributed to the final manuscript.
Conflict of interest statement
The authors report no conflicts of interest.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2020.05.030.
S.J. Kitson et al. / European Journal of Cancer 136 (2020) 169e175 175References
[1] Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-
Lahad E. Is uterine serous papillary carcinoma a BRCA1-related
disease? Case report and review of the literature. Gynecol Oncol
1999;75:300e4.
[2] Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E,
Beller U. BRCA1 germline mutations in women with uterine se-
rous papillary carcinoma. Obstet Gynecol 2000;96:28e32.
[3] Kaplan EJ, Caputo TA, Shen PU, Sassoon RI, Soslow RA. Fa-
milial papillary serous carcinoma of the cervix, peritoneum, and
ovary: a report of the first case. Gynecol Oncol 1998;70:289e94.
[4] Thompson D, Easton DF, Breast Cancer Linkage C. Cancer
Incidence in BRCA1 mutation carriers. J Natl Canc Inst 2002;94:
1358e65.
[5] Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P,
et al. The incidence of endometrial cancer in women with BRCA1
and BRCA2 mutations: an international prospective cohort
study. Gynecol Oncol 2013;130:127e31.
[6] Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N, et al.
BRCA germline mutations in women with uterine serous carci-
noma–still a debate. Int J Gynecol Canc Off J Int Gynecolog
Canc Soc 2010;20:1531e4.
[7] Levine DA, Lin O, Barakat RR, Robson ME, McDermott D,
Cohen L, et al. Risk of endometrial carcinoma associated with
BRCA mutation. Gynecol Oncol 2001;80:395e8.
[8] Breast Cancer Linkage C. Cancer risks in BRCA2 mutation
carriers. J Natl Canc Inst 1999;91:1310e6.
[9] de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van
Wezel T, van Asperen CJ, et al. Linking uterine serous carcinoma
to BRCA1/2-associated cancer syndrome: a meta-analysis and
case report. Eur J Canc 2017;72:215e25.
[10] de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG,
Segal JP, Puranik R, et al. Germline BRCA-associated endome-
trial carcinoma is a distinct clinicopathologic entity. Clin Canc
Res Off J Am Assoc Canc Res 2019;25(24):7517e26.
[11] Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA,
Martin KL, et al. Risk of uterine cancer for BRCA1 and BRCA2
mutation carriers. Eur J Canc 2017;84:114e20.
[12] Reitsma W, Mourits MJ, de Bock GH, Hollema H. Endometrium
is not the primary site of origin of pelvic high-grade serous car-
cinoma in BRCA1 or BRCA2 mutation carriers. Mod Pathol Off
J U. S. Canad Acad Pathol Inc 2013;26:572e8.
[13] Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA,
Levine DA, et al. Uterine cancer after risk-reducing salpingo-
oophorectomy without hysterectomy in women with BRCA mu-
tations. JAMA Oncol 2016;2:1434e40.
[14] Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P,
et al. Risk factors for endometrial cancer among women with aBRCA1 or BRCA2 mutation: a case control study. Fam Cancer
2015;14:383e91.
[15] Saule C, Mouret-Fourme E, Briaux A, Becette V, Rouzier R,
Houdayer C, et al. Risk of serous endometrial carcinoma in
women with pathogenic BRCA1/2 variant after risk-reducing
salpingo-oophorectomy. J Natl Canc Inst 2018:110.
[16] Kitson S, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S,
et al. PRE-surgical Metformin in Uterine Malignancy (PRE-
MIUM): a multi-center, randomized double-blind, placebo-
controlled phase 3 trial. Clin Canc Res Off J Am Assoc Canc Res
2018;25(8):2424e32.
[17] Centre for Cancer Genetic Epidemiology UoC. EMBRACE
study. 2017.
[18] Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M,
Bhaskar S, et al. A reliable method for the detection of BRCA1
and BRCA2 mutations in fixed tumour tissue utilising multiplex
PCR-based targeted next generation sequencing. BMC Clin
Pathol 2015;15:5.
[19] Cancer Research UK. Uterine cancer incidence statistics. 2019.
[20] Evans DGR, Harkness EF, Brentnall AR, van Veen EM,
Astley SM, Byers H, et al. Breast cancer pathology and stage are
better predicted by risk stratification models that include
mammographic density and common genetic variants. Breast
Canc Res Treat 2019;176:141e8.
[21] Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ,
Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG)
consensus review for uterine serous carcinoma. Int J Gynecol
Canc Off J Int Gynecolog Canc Soc 2014;24:S83e9.
[22] Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN,
Longacre TA, et al. Uterine papillary serous and clear cell car-
cinomas predict for poorer survival compared to grade 3 endo-
metrioid corpus cancers. Br J Canc 2006;94:642e6.
[23] Breslow NE, Day NE. Statistical methods in cancer research.
Volume II–The design and analysis of cohort studies. IARC Sci
Publ 1987:1e406.
[24] Cancer Research UK. Uterine cancer statistics. 2016.
[25] Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N,
Moller P, et al. Hormone replacement therapy after oophorec-
tomy and breast cancer risk among BRCA1 mutation carriers.
JAMA Oncol 2018;4:1059e65.
[26] Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V,
Perniola G, et al. Hormone replacement therapy after prophy-
lactic risk-reducing salpingo-oophorectomy and breast cancer risk
in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit
Rev Oncol-Hematol 2018;132:111e5.
[27] Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P,
Gilmour K, et al. Measuring the biological effect of presurgical
metformin treatment in endometrial cancer. Br J Canc 2016;
114(3):281e9.
